For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
The Merck & Co drug’s failure in small-cell lung cancer prompts a theory and leaves the way clear for Roche and Astrazeneca.
If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.
The anti-CD19 MAb is Morphosys’s lead pipeline asset, and an imminent filing could see it approved next year.
A bidding war has netted Sarepta the largest-ever licensing deal for a cell or gene therapy. Can Roche make it work?
Despite the recent flurry of gene therapy deals there is still a fairly extensive list of affordable companies out there.
Available to download for free now, our annual preview takes a data-driven look at 2020. Uncover biopharma’s biggest growth drivers, and see where the money is flowing.
Data and M&A lifts buoyant biopharma companies from Fate Therapeutics to Rocket, though on share price gain Forty Seven wins Ash 2019.
Disappointing data in a small neoadjuvant trial testing Tecentriq in triple negative breast cancer suggests that once again Keytruda may have an edge.